COMPASS Pathways Archives

Psychedelics News

COMPASS Pathways

Industry

23 May 2022

COMPASS Presents Psilocybin Study to American Psychiatric Association

Positive data from phase IIb study shows potential of COMP360 psilocybin therapyin treatment-resistant depression...

By Microdose NewsDesk

Don’t Miss

16 May 2022

News You Might Have Missed: May 16th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

10 May 2022

COMPASS Pathways to Fund Study of Psilocybin for Autism

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults...

By Microdose NewsDesk

Don’t Miss

9 May 2022

News You Might Have Missed: May 9th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic industry news to help you catch up and stay informed....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

9 Nov 2021

COMPASS Pathways Announces Positive Results From Groundbreaking Phase 2b Trial

The industry has been waiting for this....

By Jason Najum

Press Releases

8 Jan 2021

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care Read more on Microdose...

By Microdose

Press Releases

6 Jan 2021

COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferences

London, UK, Jan....

By Microdose

Press Releases

12 Nov 2020

COMPASS Pathways plc announces financial results for third quarter 2020

Highlights include $146....

By Microdose

Press Releases

9 Nov 2020

COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care

London, UK – 9 November 2020 Read more on Microdose...

By Microdose

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result